Latest Period
Q4 2025
Security Snapshot
AEON Biopharma, Inc. - Common Stock (AEON) Institutional Ownership
CUSIP: 00791X209
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
22
Shares (Excl. Options)
2,443,029
Price
$1.10
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- AEON on NYSE
- Shares outstanding
- 11,898,571
- Price per share
- $0.94
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 2,443,029
- Total reported value
- $1,667,217
- % of total 13F portfolios
- 0%
- Share change
- +1,078,582
- Value change
- +$712,814
- Number of holders
- 22
- Price from insider filings
- $0.94
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- AEON - AEON Biopharma, Inc. - Common Stock is tracked under CUSIP 00791X209.
- 22 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 22 to 19 between Q4 2025 and Q1 2026.
- Reported value moved from $1,667,217 to $2,694,346.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 22 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 00791X209?
CUSIP 00791X209 identifies AEON - AEON Biopharma, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00791X209:
Significant Owners of AEON Biopharma, Inc. - Common Stock (AEON) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Chernett Jorey | 9.9% | $564,250 | 1,128,500 | Chernett Jorey | 27 May 2025 | |||
| Alta Partners LLC | 2.1% | -60% | $192,400 | -$259,078 | 249,870 | -57% | Alta Partners LLC | 30 Sep 2025 |
| Dauntless Investment Group, LLC | 9.7% | $44,372 | 108,224 | Dauntless Investment Group, LLC | 26 Feb 2025 |
As of 31 Dec 2025, 22 institutional investors reported holding 2,443,029 shares of AEON Biopharma, Inc. - Common Stock (AEON). This represents 21% of the company’s total 11,898,571 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of AEON Biopharma, Inc. - Common Stock (AEON) together control 21% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Dauntless Investment Group, LLC | 18% | 2,131,852 | +89% | 5.3% | $1,324,924 |
| VANGUARD GROUP INC | 0.84% | 100,333 | +1.8% | 0% | $110,366 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.51% | 60,134 | +28% | 0% | $66,146 |
| XTX Topco Ltd | 0.48% | 56,852 | +252% | 0% | $62,537 |
| Blue Owl Capital Holdings LP | 0.36% | 43,395 | +2.5% | 0.01% | $47,735 |
| Laird Norton Wetherby Trust Company, LLC | 0.13% | 15,000 | 0% | $16,500 | |
| TWO SIGMA SECURITIES, LLC | 0.11% | 13,180 | 0% | $14,498 | |
| CITADEL ADVISORS LLC | 0.1% | 11,642 | 0% | $12,806 | |
| UBS Group AG | 0.03% | 4,052 | +240% | 0% | $4,457 |
| BlackRock, Inc. | 0.02% | 2,834 | 0% | 0% | $3,117 |
| BANK OF AMERICA CORP /DE/ | 0.02% | 2,382 | +0.25% | 0% | $2,620 |
| WOLFF WIESE MAGANA LLC | 0% | 567 | +746% | 0% | $624 |
| DUPONT CAPITAL MANAGEMENT CORP | 0% | 170 | 0% | 0% | $187 |
| MORGAN STANLEY | 0% | 150 | 0% | 0% | $165 |
| SBI Securities Co., Ltd. | 0% | 105 | -0.94% | 0% | $116 |
| Steward Partners Investment Advisory, LLC | 0% | 100 | 0% | 0% | $110 |
| GHP Investment Advisors, Inc. | 0% | 95 | 0% | 0% | $105 |
| WELLS FARGO & COMPANY/MN | 0% | 90 | 0% | 0% | $99 |
| MAI Capital Management | 0% | 58 | 0% | 0% | $64 |
| CIBC Private Wealth Group LLC | 0% | 33 | 0% | 0% | $36 |
| METEORA CAPITAL, LLC | 0% | 4 | 0% | $4 | |
| DANSKE BANK A/S | 0% | 1 | 0% | 0% | $1 |
| JANE STREET GROUP, LLC | 0% | 0 | -100% | $0 | |
| StoneX Group Inc. | 0% | 0 | -100% | $0 | |
| BARCLAYS PLC | 0% | 0 | -100% | $0 |
Institutional Holders of AEON Biopharma, Inc. - Common Stock (AEON) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,733,255 | $2,694,346 | +$440,298 | $0.98 | 19 |
| 2025 Q4 | 2,443,029 | $1,667,217 | +$712,814 | $1.10 | 22 |
| 2025 Q3 | 1,364,447 | $1,103,333 | +$78,032 | $0.81 | 21 |
| 2025 Q2 | 1,271,217 | $585,730 | -$147,232 | $0.76 | 18 |
| 2025 Q1 | 1,526,776 | $884,785 | +$884,785 | $0.58 | 15 |